Hengrui pharmaceutical sglt-2 inhibitor hengglijing was approved in China
On December 31st, the latest announcement of the official website of the China National Drug Administration, the listing application of proline Heng Ge Jing Jing, a SGLT-2 inhibitor of Hang Rui medicine, has been approved for improving glycemic control in adults with type 2 diabetes. Sglt-2 inhibitor reduces blood glucose by reducing renal reabsorption of glucose. It is a kind of non insulin dependent hypoglycemic drugs, and there is basically no risk of hypoglycemia.
This text is a result of machine translation.
Briefing Yesterday 10:54 AM
· Healthcare
Heavy bomb in the field of hypoglycemic! Lilly tirzepatide approved for listing
In-depth
Healthcare, Financials
Exclusive Interview with Zhou Mi, Managing Partner of Puhua Capital
“I entered the venture capital industry in 2008. I experienced the financial crisis in 2009 and the boom of the classical venture capital model from 2011 to 2015. Having experienced many ups and downs, I believe that venture capital will tide over the tough period and usher in new opportunities.”
May 12, 2022 05:41 PM
Briefing May 11, 2022 03:53 PM
· Healthcare
Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1
Briefing May 11, 2022 02:46 PM
· Healthcare
Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped
Apr 18, 2022 06:30 PM
Apr 22, 2021 03:11 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Briefing May 11, 2022 02:18 PM
· Healthcare
The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested
Briefing May 10, 2022 09:32 PM
· Healthcare
Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases
Briefing May 10, 2022 05:23 PM
· Healthcare
Beijing will carry out data collection standardization pilot in the field of digital medicine
Healthcare
R&D of Anti-COVID-19 Drugs is Blooming in China
Anti-epidemic stocks moved higher in early trading of the Hong Kong Stock Exchange today, with Kintor Pharma-B (Chinese: 开拓药业,09939:HK) and Shandong Xinhua Pharmaceutical (Chinese: 新华制药,00719:HK) leading the rally on the back of thriving R&D of anti-coronavirus drugs.
Yesterday 02:15 PM
Briefing Apr 27, 2022 06:47 PM
· Healthcare
Medtronic's world's first self expanding pulmonary valve was first-class recalled
Briefing Apr 26, 2022 07:38 PM
· Healthcare
Yikai capital released the first set of digital collections of Chinese investment and financing institutions
Briefing Apr 26, 2022 03:52 PM
· Healthcare
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
Briefing Apr 26, 2022 03:43 PM
· Healthcare
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Briefing Apr 26, 2022 11:20 AM
· Healthcare
Yanye said that its Xinguan oral drug s-217622 can quickly eliminate the virus
Briefing Apr 26, 2022 11:11 AM
· Healthcare
Bojian abandons Alzheimer's disease drug aduhelm and goes public in the EU
Briefing Apr 25, 2022 06:13 PM
· Healthcare
Baiyang pharmaceutical released its first annual report after listing, with double growth in revenue and net profit in 2021
See more
Read next
In-depth
In-depth
Healthcare, Financials
Exclusive Interview with Zhou Mi, Managing Partner of Puhua Capital
May 12, 2022 05:41 PM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.